Restrospective Analysis Finds MiMedx EpiFix? As Most Effective In Rapid Resolution Of Diabetic Foot Ulcers When Compared With Two Other Skin Substitutes - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Restrospective Analysis Finds MiMedx EpiFix? As Most Effective In Rapid Resolution Of Diabetic Foot Ulcers When Compared With Two Other Skin Substitutes EpiFix® shown to have most rapid and complete wound healing, least wastage and lowest cost per patient among three advanced wound care products in retrospective analysis of data.


Restrospective Analysis Finds MiMedx EpiFix® As Most Effective In Rapid Resolution Of Diabetic Foot Ulcers When Compared With Two Other Skin Substitutes

EpiFix® shown to have most rapid and complete wound healing, least wastage and lowest cost per patient among three advanced wound care products in retrospective analysis of data.

PR Newswire

MARIETTA, Ga., July 22, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced for investors today that a peer-reviewed study, "An Evaluation of Healing Metrics Associated with Commonly Used Advanced Wound Care products for the Treatment of Chronic Diabetic Foot Ulcers," was electronically published in the July 2014 edition of Managed Care.

The retrospective evaluation examined data for three commonly available skin substitutes: Apligraf®, Dermagraft®, and EpiFix®. Data examined included rates of complete wound closure, time to healing, number of graft applications to wound closure, durability of healed wounds, and safety data. Data for Apligraf® and Dermagraft® included peer-reviewed publications of pivotal clinical study data and physician product prescribing information, as well as other pre-market approval summary documents from the U.S. Food and Drug Administration. The EpiFix® data was from randomized controlled trials of EpiFix®.

The retrospective evaluation concluded: "Although prospective comparative effective trials are needed, the differences recorded suggest EpiFix® results in the most rapid improvement and resolution of diabetic foot ulcers."

The electronic publication can be found at: http://www.managedcaremag.com/archives/2014/7/evaluation-healing-metrics-associated-commonly-used-advanced-wound-care-products.

The summary comments in this press release should be read with reference to the full abstract of the study, which includes the purpose, design, methodology, results and limitations on the study analysis.

Apligraf® and Dermagraft® are registered trademarks of their respective owners.

About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. " Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 250,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here